亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.

作者
Bo Li,Xiaoli Yang,Hao Tang,Shu Qin,Fangyi Peng,Song Su
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): e16270-e16270
标识
DOI:10.1200/jco.2024.42.16_suppl.e16270
摘要

e16270 Background: The combination of transcatheter arterial chemoembolization (TACE) plus Lenvatinib prolonged progression-free survival (PFS) and overall survival (OS) than Lenvatinib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of Lenvatinib plus monoclonal antibody against programmed cell death 1 (anti-PD1) and TACE for patients with advanced HCC. Methods: Pts with advanced HCC who treated with Lenvatinib plus anti-PD1 and TACE were enrolled. Objective response rate (ORR), PFS, disease control rate (DCR) and OS were calculated to assess the antitumor response and the treatment-related adverse events to the safety. Consecutive pts were identified from September 2021 to August 2023.The Patients were included based on the following chief eligibility criteria. After signing the informed consent form, patients received sequential treatment with TACE in combination with Lenvatinib and tislelizumab. The anti-PD1 were recommended to be used continually every 3 weeks until disease progression, or intolerable toxicity. Lenvatinib was recommended to be used continually every day until disease progression, or intolerable toxicity. Follow up TACE should be given according to the patient's condition, no more than 3 times. Results: Between Sep. 2021 to Aug. 2023, 45 were enrolled. All pts received at least one dose of study treatment. The median age was 56 years(range34,73), 4 of the pts are BCLC-B stage, 41 of the pts are BCLC-C stage.Progression occurred in 8 of 45 patients and 14 patients died. The median PFS was 13.4 months (95% CI: 10.9-15.8 months) and the median OS was 20 months (95% CI: 9.8-30.4months). Of the 45 patients, a total of 3 (6.7%) patients achieved complete response (CR), and these 3 patients were treated with surgical resection. Partial Response (PR) was achieved in 12 patients (20%), Stable Disease (SD) in 22 pts (33.3%), Progressive Disease (PD) in 8 pts (17.8%), and Objective Response Rate (ORR) in patients. The Objective Response Rate (ORR) was 33.3% and the Disease Control Rate (DCR) was 82.2%.Treatment-related adverse events included increased AST 44.4%(20/45), increased ALT 51.1%(23), increased total bilirubin 42.2%(19/45), rash 44.4%(20/45), pruritus 42.2%(19/45), gastrointestinal reaction 33.3%(15/45), abdominal pain 24.4%(11/45), sensory abnormality 20%(9/45), and arthralgias 4.4%(2/45), etc., and Grade 3 Adverse events were increased ALT 2.2%(1/45), increased AST 4.4%(2/45), increased total bilirubin 2.2%(1/45), rash 2.2%(1/45), and gastrointestinal reaction 2.2%(1/45).No grade 4 or above adverse events occurred. Conclusions: In this study, TACE plus anti-PD1 and targeted therapies showed favorable efficacy and manageability in patients with advanced HCC. Toxicity was manageable with a low incidence of grade 3-4 adverse events. There were no unexpected safety signals.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LHY完成签到,获得积分10
7秒前
11秒前
香蕉乐曲完成签到,获得积分10
30秒前
54秒前
null的应助被科研通管家采纳,获得10
1分钟前
沉静的愫完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
1分钟前
ww发布了新的文献求助10
1分钟前
1分钟前
adgn发布了新的文献求助10
2分钟前
老实的石头完成签到,获得积分10
2分钟前
2分钟前
个性鹭洋完成签到,获得积分10
2分钟前
丘比特的应助被adgn采纳,获得10
2分钟前
2分钟前
戴肉肉完成签到 ,获得积分10
3分钟前
深情安青的应助被科研通管家采纳,获得10
3分钟前
专注湘完成签到,获得积分10
3分钟前
范特西完成签到 ,获得积分10
3分钟前
忍冬完成签到,获得积分10
3分钟前
就吃一小口完成签到 ,获得积分10
4分钟前
AlexMoradi452发布了新的文献求助50
4分钟前
友好怜菡完成签到,获得积分10
4分钟前
跳跃的咖啡豆完成签到,获得积分10
4分钟前
4分钟前
4分钟前
盐水菠萝完成签到,获得积分10
4分钟前
rubbish发布了新的文献求助10
4分钟前
Wei发布了新的文献求助10
4分钟前
盐水菠萝发布了新的文献求助10
4分钟前
深情安青的应助被林楚棋采纳,获得10
4分钟前
陈淋完成签到,获得积分10
4分钟前
小巧的孤丹完成签到,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
5分钟前
大模型的应助被科研通管家采纳,获得10
5分钟前
5分钟前
所所的应助被科研通管家采纳,获得10
5分钟前
5分钟前
null的应助被科研通管家采纳,获得10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780335
捐赠科研通 7765068
什么是DOI,文献DOI怎么找? 3431528
关于科研通互助平台的介绍 2555609
邀请新用户注册赠送积分活动 2476668